文献速递肿瘤 PET/CT神经核医学

镓-68标记的NODAGA-E[c(RGDyK)]2用于神经内分泌肿瘤整合素αvβ3显像及预后判断的前瞻性II期试验

Prospective Phase II Trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT Imaging of Integrin αvβ3 for Prognostication in Patients with Neuroendocrine Neoplasms.
PubMed 文献 · J Nucl Med · 2022-08-18

该前瞻性II期试验于2017年12月至2020年11月纳入113例各级别神经内分泌肿瘤患者,99例接受镓-68标记的NODAGA-E[c(RGDyK)]2 PET/CT显像,97例可评估病灶。中位随访31个月,76%患者有阳性肿瘤病灶,高整合素αvβ3表达(SUVmax≥5.25)与无进展生存和总生存的较差预后相关。作者认为需进一步研究该显像能否成为筛选整合素αvβ3靶向治疗获益患者的预测工具。

要点

  • 99例神经内分泌肿瘤患者接受镓-68标记的NODAGA-E[c(RGDyK)]2 PET/CT,97例病灶可评估。
  • 76%患者有阳性肿瘤病灶,高级别肿瘤患者中91%有阳性病灶。
  • SUVmax≥5.25者无进展生存HR为2.11(95%CI 1.18-3.78),总生存HR为6.95(95%CI 1.64-29.51)。

核心结论

  • 各级别神经内分泌肿瘤患者中均可见镓-68标记的NODAGA-E[c(RGDyK)]2肿瘤病灶摄取,高摄取与较差预后相关。
  • 作者认为需进一步研究该PET/CT能否成为筛选整合素αvβ3靶向治疗获益患者的预测工具。

研究设计与样本

  • 前瞻性II期试验,2017年12月至2020年11月纳入113例各级别(2019年世界卫生组织分类)神经内分泌肿瘤患者。
  • 注射200 MBq镓-68标记的NODAGA-E[c(RGDyK)]2后45分钟采集PET/CT,由核医学和放射学专科医师测量肿瘤病灶SUVmax。
  • 阳性肿瘤病灶定义为肿瘤与肝脏本底比值≥2,以每例患者最大肿瘤SUVmax作为结局预测指标。
  • 随访至少1年以评估无进展生存和总生存。

主要发现

  • 113例入组患者中99例接受PET/CT,97例有可评估病灶。
  • 患者以小肠(64%)或胰腺(20%)神经内分泌肿瘤为主,93%有转移性疾病,78%为低级别肿瘤,22%为高级别肿瘤。
  • 中位随访31个月(四分位距26-38个月)期间,62例(64%)出现疾病进展,25例(26%)死亡。
  • 76%患者有阳性肿瘤病灶,高级别肿瘤患者中91%有阳性病灶。
  • SUVmax≥5.25者无进展生存HR为2.11(95%CI 1.18-3.78),总生存HR为6.95(95%CI 1.64-29.51),P值均为0.01。

关键数值与推荐

  • 阳性肿瘤病灶定义为肿瘤与肝脏本底比值≥2。
  • 高整合素αvβ3表达定义为SUVmax≥5.25。
  • 高表达者无进展生存HR为2.11(95%CI 1.18-3.78),总生存HR为6.95(95%CI 1.64-29.51),P值均为0.01。

临床怎么用

  • 作者认为需进一步研究以确定该PET/CT能否成为筛选整合素αvβ3靶向治疗获益患者的预测工具。

局限性

  • 作者认为需进一步研究以确定该PET/CT能否成为筛选整合素αvβ3靶向治疗获益患者的预测工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Integrin αvβ3, a subtype of the arginine-glycine-aspartate (RGD)-recognizing cell surface integrins, is upregulated on endothelial cells during angiogenesis and on tumor cells. Because of involvement in tumor growth, invasiveness and metastases, and angiogenesis, integrin αvβ3 is an attractive target in cancers. In this study, we applied 68Ga-NODAGA-E[c(RGDyK)]2 for imaging of integrin αvβ3 in patients with neuroendocrine neoplasms (NENs) and its potential use for prognostication. We hypothesized that 68Ga-NODAGA-E[c(RGDyK)]2 PET/CT would show tumor lesion uptake and that higher tumor lesion uptake was associated with a poorer prognosis. Methods: Between December 2017 and November 2020 we prospectively enrolled 113 patients with NEN of all grades (2019 World Health Organization classification) for 68Ga-NODAGA-E[c(RGDyK)]2 PET/CT. The scan was acquired 45 min after injection of 200 MBq of 68Ga-NODAGA-E[c(RGDyK)]2 Board-certified specialists in nuclear medicine and radiology analyzed the PET/CT measuring SUVmax in tumor lesions. Positive tumor lesions were defined as those with tumor-to-liver background ≥ 2. Maximal tumor SUVmax for each patient was used as a predictor of outcome. Patients were followed for at least 1 y to assess progression-free survival and overall survival. Results: Of 113 patients enrolled in the trial, 99 underwent 68Ga-NODAGA-E[c(RGDyK)]2 PET/CT, with 97 patients having evaluable lesions. The patients predominantly had small intestinal (64%) or pancreatic (20%) NEN and most had metastatic disease (93%). Most patients had low-grade tumors (78%), whereas 22% had high-grade tumors. During a median follow-up of 31 mo (interquartile range, 26-38 mo), 62 patients (64%) experienced disease progression and 25 (26%) patients died. In total, 76% of patients had positive tumor lesions, and of the patients with high-grade tumors 91% had positive tumor lesions. High integrin αvβ3 expression, defined as an SUVmax of at least 5.25, had a hazard ratio of 2.11 (95% CI, 1.18-3.78) and 6.95 (95% CI, 1.64-29.51) for progression-free survival and overall survival, respectively (P = 0.01 for both). Conclusion: Tumor lesion uptake of 68Ga-NODAGA-E[c(RGDyK)]2 was evident in patients with all grades of NEN. High uptake was associated with a poorer prognosis. Further studies are warranted to establish whether 68Ga-NODAGA-E[c(RGDyK)]2 PET/CT may become a prediction tool for identification of patients eligible for treatments targeting integrin αvβ3.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Carlsen EA, Loft M, Loft A, et al. Prospective Phase II Trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT Imaging of Integrin αvβ3 for Prognostication in Patients with Neuroendocrine Neoplasms. J Nucl Med. 2022. PMID: 35981899. doi:10.2967/jnumed.122.264383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。